The oral administration also ameliorates NAFLD and dyslipidemia with lower liver damage and adiposity indices, together with a reduction in the blood levels of triglycerides and total/LDL cholesterols and downregulation of hepatic genes involving lipid synthesis (e.g., SREBP1c, FAS, and PPARα) [40,41,42]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.